Climb Bio (NASDAQ:CLYM) Shares Up 8.9% – Should You Buy?

Climb Bio, Inc. (NASDAQ:CLYM)’s share price traded up 8.9% during mid-day trading on Tuesday . The stock traded as high as $17.36 and last traded at $17.8550. 133,666 shares changed hands during mid-day trading, a decline of 86% from the average session volume of 935,836 shares. The stock had previously closed at $16.40.

More Climb Bio News

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: Unusually strong call-option activity provided a bullish trading signal: investors purchased 3,024 call options, roughly 740% above the average daily volume of 360 contracts. Options activity can indicate increased expectations for further share-price gains, although it does not guarantee a positive outcome.
• Positive Sentiment: HC Wainwright raised its Climb Bio earnings estimates across multiple periods, including FY2026 EPS to a loss of $0.76 from a projected loss of $0.93, Q3 2026 EPS to a loss of $0.20 from $0.23, and Q4 EPS to a loss of $0.19 from $0.22. The firm also modestly improved its FY2027 forecast to a loss of $0.98 from $0.99. HC Wainwright maintained its Buy rating and $24 price target, above the stock’s recent trading level.
• Positive Sentiment: Climb Bio’s Phase 2 trial in China is advancing, reinforcing the company’s clinical-development narrative and potentially supporting future value if results are favorable. Climb Bio Advances Phase 2 Trial in China
• Neutral Sentiment: Reported short interest was zero shares as of August 25, unchanged from the prior report. Because the figures appear inconsistent with an actively traded public company, the data offers little useful indication of short-selling pressure.
• Negative Sentiment: The China Phase 2 progress is accompanied by a valuation concern: investors may already be pricing in substantial clinical success. That raises the risk of volatility or a pullback if upcoming trial updates fail to exceed expectations.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. HC Wainwright upped their price target on Climb Bio from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Monday. Truist Financial increased their target price on shares of Climb Bio from $17.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Guggenheim assumed coverage on shares of Climb Bio in a research report on Monday, June 8th. They issued a “buy” rating and a $35.00 price target on the stock. BTIG Research upped their price objective on shares of Climb Bio from $19.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, June 11th. Finally, Wall Street Zen upgraded shares of Climb Bio from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $23.08.

Climb Bio Trading Down 9.9%

The stock’s 50-day moving average price is $13.69 and its 200-day moving average price is $10.37. The company has a market cap of $923.57 million, a P/E ratio of -19.37 and a beta of 0.08.

Climb Bio (NASDAQ:CLYM) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.03. On average, research analysts anticipate that Climb Bio, Inc. will post -0.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Climb Bio

Several large investors have recently bought and sold shares of the stock. AQR Capital Management LLC bought a new position in shares of Climb Bio during the 1st quarter worth approximately $27,000. Goldman Sachs Group Inc. purchased a new position in shares of Climb Bio in the first quarter worth about $147,000. Marshall Wace LLP purchased a new stake in shares of Climb Bio during the second quarter worth $46,000. Qube Research & Technologies Ltd bought a new stake in shares of Climb Bio during the 2nd quarter valued at $43,000. Finally, Jane Street Group LLC purchased a new stake in shares of Climb Bio in the second quarter worth about $184,000. 69.76% of the stock is currently owned by institutional investors.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.